Q1 2021 Amneal Pharmaceuticals Inc Earnings Call
[music].
And there are 76 assets that you just launched.
And of course, and I'll go to 76.
And welcome to the first quarter 2021 conference call all participants will be in listen only mode should you need assistance and placed into a conference specialist by pressing the star key followed by zero.
After todays presentation, there will be and ask you to ask questions and I'll ask a question you May Press Star then one and you touched on and fun to withdraw. Your question. Please press Star then two please note today's event is being recorded I would now other kind of call rehab and they also head of Investor Relations Tiny day ma'am.
Good morning, and thank you for joining us for annual and first quarter 2021 earnings call.
Earlier. This morning, we issued a press release reporting our financial results.
Our press release as well as the slides that will be presented on this call are available on our website at <unk> Dot com.
We're conducting a live webcast of this call a replay of which will also be available on our website. After its conclusion.
Please note that today's call is copyrighted material and Neil.
And cannot be rebroadcast without the company's express written consent.
I would like to remind you that <unk> made during this call management's outlook or predictions for future periods are forward looking statements.
These statements are based solely on information that is now available to us.
And we encourage you to review the section entitled Cautionary statement on forward looking statements in our press release and presentation, which applies to this call.
Our future performance may differ due to numerous factors.
Many of which are listed on our most recent annual report on form 10-K, and our revised and updated on our quarterly reports on form 10-Q.
And current reports on form 8-K, which you can also find on our website and on the SEC's website at SEC Gov.
We also discuss certain non-GAAP measures you will find important information on our use of these measures and a reconciliation to U S GAAP and our earnings release.
Included in the appendix of today's presentation, you will find U S. GAAP financial metrics that correspond to some of our U S. non-GAAP measures, we reference throughout the presentation.
On the call. This morning are Suraj and <expletive> to Patel co Ceos, Tassos, Tony <unk>, our CFO and Ebola.
And Joe to discuss our chief commercial officer for the generic and specialty segments and cement, our general counsel and corporate Secretary and I will now turn the call over to share off Thank you, Tony and welcome to Emil and good.
Good morning, all and thank you for joining us this morning.
I wanted to acknowledge the public health crisis and India.
COVID-19 has challenged the world in many ways.
But even by the standards set over the last year the situation in India is very challenging and <unk>.
Access to medical care is limited.
We are working diligently with the Indian government officials charitable foundations and other pharmaceutical leaders to utilize it would expertise and resources to secure critical care and medications and equipment.
Hearts are with Hercules and India.
As well as all of those who continue to prior to COVID-19 around the world.
As an essential business. We are proud of the investments, we continue to make and protecting the health and well being local and employees.
In addition, we are also and ensuring that continuous supply of the minuses corporations and customers and the United States, our robust global supply chain is operating well and the fruits of the procurement and quality and manufacturing teams have been truly heroic.
Finally, this latest COVID-19 outbreak is a reminder of the dependency of the U S generics pharmaceutical industry on quality and manufacturing. We believe it remains critically important to make more products and America quarter Micah.
And really and new significant domestic manufacturing base superb quality record and the U S domiciled and enabled us to work closely with federal and state legislators and public policymakers to provide meaningful solutions and.
We look forward to sharing updates as we make progress.
Turning now to our financial and operating and it goes I am extremely pleased with our first quarter results and how the full year is shaping up we remain confident that over momentum display and in total will commercialize and pipeline assets solid execution will deliver another year of strong top and bottom line.
Performance consistent with our guidance, let me now provide you with an update on key initiatives across our business.
And we believe companies and our industry are only as strong as the router and the organizations.
Oasis is growth and we continue to invest and product development and both generics and specialty.
And genetics.
We have established and well oil and engine to replenish our development portfolio and drive increasingly complex product launches.
And our strong innovation capabilities are a major reason.
We have delivered growth in and industry experiencing secular pressure.
While our base business faces competition, our R&D team is constantly moving us up the value chain with higher barrier to entry products that have longer tails of revenues and profits.
And especially we are acutely focused on executing the development plans for <unk>.
And cash use specialty pharmaceuticals programs, we acquired earlier this year simple will touch on innovation and greater detail shortly.
Secondly, we are excited to Seo and manufacturing and supply chain continue to improve every quarter. When we came back it goes on and off for US probably goes optimize our global operations and reduce excess overhead and cost improve margins and genetics and ultimately increase profitability.
We are executing growth towards these goals as genetics gross margin and post quarter grew to 45 per se going forward, we are pursuing additional efficiencies to improve margins over time.
Third we know that execution of strategic accretive and creative transactions and help us and <unk> growth.
Just after the end of first quarter, we completed our acquisition of cash use specialty pharmaceuticals, with Kashi and new games base best in class small molecule formulation and development talent.
Which we expect will drive substantial organic long term value across our portfolio.
Also gained several near term MBA programs across neurology and endocrinology that we expect to begin to launch as early as 2023.
But we're not stopping there given the other existing commercial infrastructure and neurology and endocrinology and we are pursuing complementary commercial stage assets as well as late stage clinical programs to provide near term synergistic revenues revenue streams.
We believe we are uniquely positioned to drive substantial value to all stakeholders and process and strengthen our balance sheet over time.
Finally, we continue to grow what I would share distribution business, where we saw solid topline and profitability performance this quarter.
And as we have discussed in the past.
<unk> represents the strategic long term opportunity for us as we focus on referred to and channel This business as Boyd.
Hi.
Favorable tailwind, including the continued stream of branded pharmaceuticals going genetics every year as.
As we look towards the rest of 2021 and beyond <unk>.
<unk> and I could not be more excited about our business and confident and our strategic direction.
Today, and neither is truly firing on all cylinders and we expect continued strong financial and operational performance as we move forward.
With that I'll now turn the call over to chip.
Good morning, everyone. Thank you Gerard.
As always I would like to begin by recognizing our employees, whose tremendous dedication inspires Chi Doug and.
And every day and drives our continued success and making healthy possibly growth.
Team's relentless commitment to delivering very thing all of our customers and patients even in these trying times is truly remarkable toward employees. We thank you for your support and I filled with gratitude for all you have one chip or.
And our employees and India have demonstrated amazing inquiries and we are actively supporting them to ensure they get the care they need in light of the most recent COVID-19 outbreak.
The other team has continued to ensure our supply chain remains strong and the flow of products is uninterrupted from the beginning of the pandemic, we focused on building and even more resilient global supply chain, which has led to strong inventory levels across all locations. These are.
Unprecedented times and we.
They report those who have lost family members to the stable wireless and India and across the World now let me provide a few key business updates.
Bob.
Per share that we have.
Advancing key initiatives across the company.
And to improve efficiencies, which will save cost and expand margin growth.
Example, while we manufacture most of our genetics.
We are transferring several products from external manufacturing partners.
Through our facilities, which will reduce cost and improve supply chain and many of many of these types of initiatives will help improve our gross margin in a sustainable way and as always we continue to uphold the highest standards of good manufacturing practices and integrity across every day.
Aspect of our business from the very beginning we have prioritized quality and compliance at all levels.
It is truly emlen, the DNA and part of our culture.
Dark space R&D, the growth engine portable and industry and we continued investing in our future pipeline I will start with genetics. We believe that we added an exciting thing for and need to go as we begin to see the benefits of the transition of our development activity.
And it's complex dosage forms drug device combination and other high value programs or 80% of our pipeline is non oral solid products and an increasing share of that drug device combination.
<unk>, which we launched in March and is a complex automotive patch is a perfect example of our genetic strategy in action and therefore.
Themed CGT designation, which granted 180 days of exclusivity and given the complexity of it development and manufacturing we believe it will have a limited competition even post exclusivity.
<unk> genetics approved CTD designated Industrywide MTS has launched can by far the highest number of industry looking forward, we will continue and repricing of our pipeline, we expect to deliver at least six to selling high value products and.
It will be the.
In addition, we are actively looking to expand our high value complex generic portfolio into select international markets, while external partners or existing partnership with postal is proceeding nicely together, we have already filed all products in China and expect to file on other fiber by the end of the year.
And this is just the first of multiple international collaborations overall with the global expansion is another record for long term sustainable growth and.
Next biosimilar will be and increasingly meaningful component of our pipeline going forward as we have shared in the past we think the biosimilars market will behave more like complex generics overtime.
And we have a core spending high quality manufacturing and <unk>.
And <unk> and strong commercial execution will position us extremely well in this space.
Currently we have filed three biosimilar products, which we expect to launch over the next couple of years beyond that and we are actively evaluating additional opportunities via partnership models.
And we can be first or second to market. We believe biosimilars will be a key strategic approach every day for us over the next five to 10 years.
Turning to our specialty pipeline IPX two or three is the most advanced of our work for specialty pipeline programs and is currently in phase III clinical trials with an estimated launch in 2023 as a reminder, IPX two or three is our next generation product for Parkinson's disease.
We expect the product will offer us a material improvement over rytary and existing therapies in.
And the United States, 60% of PD patients are roughly 600000 people are on some form of levodopa therapy to help manage offline.
Rich or periods of drastically reduced motor function due to low levels of dopamine and need.
It really started with overall levodopa is a first line therapy for Parkinson's.
Our current leading product rytary and extended release <unk>.
And overall libido product designed to provide better on time for moderate and severe patients compared to generic immediate release.
In this patient population and our or to offer additional all time can be a large improvement and quality of.
At $9 million below Q1, 2020, reflecting three dynamics first higher gross profit primarily due to a favorable product mix and operating efficiencies this year.
Second, we're making substantial investments in our R&D and sales and marketing to drive long term growth.
Third the tough comparison to Q1 of 2020.
Our adjusted EBITDA of $134 million was substantially higher than the 107 million average for the remaining three quarters of the last year.
Adjusted diluted EPS of <unk> 20.
It was flat to Q1 2020, as our adjusted EBITDA performance and low interest expense on.
The very high prior year comps.
Again last year's first quarter of 2017, EPS was much higher than the 14.
Average over the remaining three quarters of 2020.
From a cost perspective operating cash flow of $148 million was ahead of our expectations and well ahead of the night over $49 million, we generated in Q1 2020.
We need to be mindful that this metric is inherently variable net.
Other less the strong performance was driven by top line performance.
Lower DSO and some favorable timing.
As a result of our strong financials in the quarter, we strengthened our balance sheet and our financial flexibility.
Constant cash equivalent in March 2021 was $456 million compared to $347 million in December 2020, and our net debt to adjusted EBITDA ratio improved to five one X compared to $6 two X in March 2020.
In summary, we're pleased with our top line performance higher levels of profitability cash generation on an improved balance sheet.
And secondly, our full year 2021 guidance remains unchanged and we remain confident in our financial and operating performance for the remainder of the year with that let me turn the call over to Sue I think you doses. We are pleased with other continued positive momentum through the start of 2021 as we continue to execute.
Gains on.
And Neil to Boingo strategic vision growth.
A long term sustainable growth.
Now like to turn the call over to the operator to take your questions.
Yes. Thank you.
Now begin the question and answer session.
Question You May Press Star then one on your thoughts on found.
If you every day and speaker phone. Please pickup your handset before pressing the keys to withdraw your question. Please press Star then two.
At this time, we will pause momentarily to assemble the roster.
And the first question comes from Gregg Gilbert with Trust.
Thanks have a few shrug I want to start with a high level strategic question I understand the desire for companies, including yours to want to move up the value chain and more durable products and brands.
I certainly understand that but also.
Wonder why the generic industry in the U S Hasnt consolidated more given.
What we've seen on the customer side do you think that's in the cards.
Independent of your Standalone strategy.
Let me ask the other questions right upfront toss us maybe you could comment a little bit on the half care strength and how lumpy that is on what some of the drivers are there.
And lastly for 10 two.
As generic Nexplanon, our project that is interesting to you and perhaps underway and curious.
How challenging something like that would be compared to other projects you've had your team work on thank you.
Greg So crashed this morning.
Good morning consolidation in genetics that the quarterly <unk>, yes.
As you know.
It is tough and the reason it is done.
The FTC.
Likewise diverse many products, we went through with impacts merger, we had to go back and forth with the agency and ended up divesting low value away and also moving the products from.
The other plans apex plants to EMEA, we lost a lot of revenue between.
So it becomes very hard you look back and say, okay. Why should we do that of course.
Lots of synergies, we can pick up where the overlaps are so many so if we find the target with outerwear labs.
Really good.
I hope.
<unk> needed the consolidation as much just what form it comes in.
New players without over the last day gain much switch when it goes generic diverse mango is good.
There are a couple of small companies do they consolidate together good good for the industry.
And we need that.
As you know Indian companies are really hard time doing anything so they go on quarter legacy of the families for many years to go so they do not consolidate.
It's a little bit uphill low cycle brand so that question Dave.
That goes on every carrier.
Yeah. Good morning, peso income and try let me try this work so.
<unk> overall is growing nicely. So last year, we did about almost $300 million.
This year it will grow mid double digit so we feel good about the topline growth.
Perfect ability.
Knew that when we did the deal profitability from the business is around high high double digits. So last year was 18%.
In Q1.
We're seeing that 20%.
So we're pleased with that improved level of profitability.
Other things, we like about the business about more than 50% of that $300 million growing double digit. This year is the government business and what we like about this many of the contracts are long term contracts. So it gives us a nice stable platform that we can grow over time and for that reason, we cannot turn on the growth rate.
Overnight right.
It Embeds us without without government.
Customers and his team has a lot of expertise. So over time, who are looking to grow that segment not only by leveraging third party products, but also MTL products, which as you can imagine provide.
Provide.
It's much more profitable growth there the rest of their business is a number of other a number of other more distribution like businesses with low single margin business.
And that's been growing nicely and that's what we're looking for more operating efficiencies over time, So I think.
Overall, I think that business again this year on growth mid double digits I think for the next few quarters will be low.
These two low nineties.
In terms of quarterly revenues and profitability should be in that 18% to 20% gross margin hopefully Greg.
And just to <unk>, but we're also growing the unit goes business by launching eight to 10 of our own liquid products out of range, Brian Swift and Juicy site, so that should be a nice.
What I would say next year.
Jim.
Hi, Greg good morning.
So good question on next volume so am Neal.
As you know has been investing into a complex and we continue to work the value chain and the product. They can explain that reaches a drug device combination and planned broader picked.
On the golf ball the most complex data from developed land and from the day rate perspective, and also how to conduct and work with FDA with patchy with acquisitions, we acquired that some of the talent that is required.
I will on getting to that particular product, but I mean, we have the good knowledge.
On how to download the PDF.
Five years long.
Implant products, we had a very good drug day rate.
Doug the weighted group within the organization, we understand their formulation and the other challenges.
It gets 30 day Doug.
Regulatory requirements wed absolutely.
Is moving up and it's part of our portfolio not the particular product, but anti drug device combination in blind guided there is something we are already excited and we have the knowledge and we're working aggressively to bring that to the market.
Thanks, gentlemen.
Thank you and the next question comes from Daniel was weighted with RBC capital markets.
Hey, good morning, Thanks for the question maybe.
Maybe sticking with the Big picture theme as we think about the business longer term in your view what is the ideal revenue mix between generics and specialty and also I guess U S vs. O U S. Clearly right now you're still more heavily weighted towards U S generics, but what would you ideally like to see when we look at the business five years from now.
And how does business development play into that.
And second how should we think about the cadence of additional generic new launches over the remainder of this year and how important are those to the anticipated step change increase in generic revenue that you mentioned.
Thank you Daniel.
So the big picture, how do you see.
CMT and growing sales.
We need to go.
So.
We said the complex genetics is a driver of the business within generics.
Within complex genetics, all kind of dosage form that change you mentioned that device products the inhalation products.
<unk> products and as we have said it a year ago that biosimilars, we put them in there.
<unk> genetics, so that segment going from somewhere at the 141 5 billion to a higher level than prior years, we're not going to give you exact number now but there is enough growth.
For us because of all these scientific.
Capabilities and investment we have made over the years to come.
So it will be excellent growth in that one segment of the business the specialty.
We have our own pipeline, we havent given forecast for that pipeline IPX, two or three years moving nicely.
So as <unk> $1 seven and we are very serious on and we got the platform. We've got the technology and one thing on Neal.
Well is once we get in we do it we finished the job. So we it's a long term volume put US 510 years, who will build the specialty business to be.
To be at a great level on it more.
More contribution on EBITDA than revenue.
Hi.
I don't want to say the mix exactly but it is on.
Tremendous growth trajectory and also it will be complemented by accretive strategic M&A.
Because we have the strength, we got the cash flow we got the cash.
Complex generics complementing the specialty so.
From a Parkinson's Parkinson DC side, we like to consolidate as many products as we can.
Same thing on endocrinology is our key to incomes and then there is more to come so really excited and where are you targeting on on those two areas.
Yes, good morning.
Yes, just in terms of overall new product launches are critical to us, but we are really not rely on any additional new product launches to lead to that step change I spoke to.
Just on the product portfolio that we currently have we're very confident on the step change number one.
Number two as.
As new products come in those those new products will be fueling growth, mostly towards Q4 and into next year.
Great. Thanks for the color.
Thank you and the next question comes from David <unk> with Piper Sandler.
Mike.
Okay.
Thanks, So just a couple so on the Biosimilars.
Yes.
Yep.
I know that this is a partnership model, but how should we think about your net economics and how these these three opportunities you've identified.
What kind of margins.
They'll have relative to your overall generic.
Margins given those the shared economics.
So that's number one.
And then number two is you've talked about other.
Other programs other.
Similar programs when are you going to be in a position to identify those other opportunities do you expect those other opportunities to have better economics of similar economics to.
To avastin in the and the G CSF.
And then lastly is there anything that you can add on the Copaxone generic.
Is this still part of your expectation that you.
Do you expect that opportunity to bear fruit later this year. Thank you.
Thank you David.
So in Biosimilar strategy.
As you pointed out it's a partnership model to begin with.
Which is very cost effective for us.
The weighted and we wanted to see how the lumps because we did not want to spend or invest $150 million to $200 million per.
Total biologic and respected Nance the ticket.
Ticket packages. So we wanted to see how the adoption of Biosimilars, which is all playing now nicely.
Now and over the next 10 years, we see Biosimilar is a great business and not only biosimilars. It will then just like in small on more than cooler firefighter E. Twos Biosimilars may end up in Dubai Baker's on follow on.
<unk>, biologics, because which couldnt be broad earlier in the market. So we've been very diligently working.
Last couple of other use to identify great partners.
We understand the manufacturing is a key I would.
80% value to two very high end manufacturing and consistent manufacturing.
We are working on our strategies on how do we become champions League on the complex generics for the manufacturing of Biosimilars and then R&D, we will establish other capabilities sooner than later margins, we expect them to be in.
Okay.
Split is almost like 60% in our payroll 40 was on good partner.
We probably will continue with that model, which gives us around 25% to 30% EBITDA by product. If we do it in house whenever we start doing it obviously it will go up to 35 plus percent.
So thats the plan.
And David when we announced the next partnership this year.
Okay.
And then with your last question on Copaxone.
As we are working in.
The product tanker will launch later this year or early first quarter correct.
Great. That's helpful. Thank you.
Sure.
Thank you and the next question comes from Elliot Wilbur with Raymond James.
Hi, Good morning. This is Lucas Lee on for Elliot and thanks for the question.
The question I have is what drove the gross margin upside during the quarter.
Stable and how does that impact your prior expectations around generic gross margin trends.
And as a follow up how are you thinking about the potential generic competition on zomig. Thank you.
Sure I can day Lucas good morning, we just assets.
Yes.
We were incredibly pleased on the on the gross margin performance and it was.
So every business expanded margins, which is something we're very focused on improving profitability.
Generics had a great quarter.
With margins at about 45%, we believe those on a sustainable my gut feeling is I think we're going to see some moderation alright, the low forties somewhat duration.
I think we work on it finished the year on the generic side most likely in the low <unk>.
Which as you know with a substantial increase versus that 38%, we delivered last year and authority on the 35%. We finished 2019, so as you can see.
We are executing in terms of what we had said over the last couple of years, we see generic commodity is growing over 40%. So they will be pleased to cross that.
Average this year.
That's in terms of our expectations, so pretty much sustainable and it's the same thing across the remaining other two parts of the business.
On on.
On generic Zomig I mean, this was not overall one of the things. We are proud about what we have created we have created very very <unk> business much more so that three years ago.
So we have omnicare.
Part of the business specialty has grown we have a portfolio of generic products over 250 products.
So we're not dependent on any single products.
With us on genomic, let me turn it over to Joe to kind of give us a little bit more insight sure. Thanks assets with respect to specific generic competition on zomig nasal spray. We are aware of two filers that are already publicly known but we always do assume that someone else could be coming to market.
Have preemptively launched authorized generic earlier this year, we've got sufficient inventory of both label that we've taken steps to maximize the value.
The product regardless of the number of generic competitors that come to market at the end of day.
Thank you that's very helpful.
Thank you and the next question comes from Dana Flanders with Guggenheim.
Okay.
Great. Thank you very much further questions I just had two.
My first is I was wondering if you could comment on just based on business generic pricing trends. We are hearing some comments from the supply chain and other manufacturers.
That theyre seeing a little bit more pressure this year kind of independent of competition. So I'm, just wondering if youre seeing that as well.
And then my second question I was wondering if you could comment on just the unfortunate and sad situation.
Going on in India, with with COVID-19 and wondering if you are seeing or expecting to see kind of shortages start to pop up.
Impacting the U S market and just how and deals.
Overall supply chain is just relatively positioned.
Yes.
This is Todd I'll take the first question on pricing.
And we're seeing just a high level, we're seeing consistent.
Behavior as you are hearing from some of the other manufacturers.
But also I want to point out this is exactly what we planned this year. So as a reminder, our guidance we assumed.
Mid to high single digit deflation as you mentioned, it's coming certain areas certain areas, it's coming a little a little worse than that but our ability right to get new product launches actually ahead of our own expectations and our ability of our supply chain.
To drive operating efficiencies.
And the new market share growth that we're seeing by the commercial team is offsetting that.
And ultimately increase our profitability in a sustainable way so pretty much very happy how the company is dealing with this.
And so forth.
<unk>.
In terms to India on let me, let me turn it over to Iraq I think that's a good perspective on that thank you doses. So situation is very good.
On the local lockdowns, but pharmaceuticals being essential industry.
Is allowed to operate.
Sure.
Inventory levels are.
Sure.
Yes.
And Neil is very good three plus months and we have secured.
And if you count overall.
Overall inventories almost four to six months.
So we don't expect as far as Neil is concerned any shortages from our product others.
Main page based on where they're located and how much free planning how they've done.
But for now next month or two.
<unk> be fine.
We expect the situation to improve hopefully after one month.
And then Neal India, we're doing.
We can to help the situation.
Oxygen concentrator.
<unk>.
Working on.
Supplying your donating readiness.
And steroids products.
Are you on Indian government licenses too so we never sold anything to local market from.
All other U S FDA approved plant in India.
So and everybody's.
Assisting many countries have as you know offer lots of help so.
<unk> seem to be enough in Brazil, I was on the call with Gilead, a 15 million, while they would produce to see this month.
So.
That all tying to help same thing with Pfizer on hopefully the more vaccines.
We will be available.
Besides expenses an acre.
This is where again.
And we hope net includes soon thank you.
And just to add one point there were already proactively recognizing menu of COVID-19 I mean, India employees, the large population or our employee base has been vaccinated and.
That has led to very good attendance and that strong supply chain.
We are working diligently with everyone to make sure we do everything to provide help and support.
Whether it was supply chain still in this current situation is really really strong.
Thank you and the next question comes from Nathan Rich with Goldman Sachs.
Good morning, and thanks for the questions.
Maybe starting with you I just wanted to make sure that I understood that.
Revenue cadence or the generic segment, you called out the $23 million headwind related to the mild flu and cold season.
I'm, assuming that that revenue doesn't come back over the balance of the year is that a fair assumption and if so it looks like your kind of underlying view of the business got better it sounds like pricing trends have been consistent.
But you did mentioned the traction with the new product introduction. So is that what is kind of driving the implied increase.
The increase in outlook over over the remainder of the year.
And then just as a follow up.
As we think about the margin opportunity for complex generics.
How should we be thinking about.
Those margins relative to maybe the generic segment average I think you had maybe you mentioned biosimilar margin EBITDA margins being north of 30% if I got that number right where would you feel like that kind of a complex generic average kind of be relative to.
Margins for that segment. Thank you.
So good morning, so yes.
Yes, I think thats $23 million right in Q1 related.
Related to.
<unk>.
Low flu season et cetera, that's not going to come back so I think youre spot on.
But nevertheless.
But.
The rest of the year remains unchanged or slightly ahead of our own initial projections.
That really reflects.
New product introductions, and the subs and primarily as a family launch just doing it.
Extremely extremely well.
That's number one and the margins I think we see sustainability in the low <unk> for the rest of the year on the generic side. So so.
Well.
For increased profitability over all of the generics versus our initial expectations.
In terms of the new products the complex generics.
Overall, the generic margins it is in the low forties right. So you can assume that that's substantially more so on that substantially more than that and primarily during the first call. It six seven months when we have an exclusivity so that that kind of bodes well as we think about next year.
The year after that about improving gross margins on the generics.
The other generics.
They are similar.
I think the early stages I think that first three biosimilars we have.
On in place just because there is just more competition at this point in time.
And because it's much more partner I think the EBITDA that <unk> talked about earlier on call. It.
The 30% I think thats a good a good number over time as we enhance our manufacturing capabilities and our internal.
Expertise I think we see those going up from there.
Yes, Nathan share OXXO would we see durability for the complex generics and Biosimilars. The complex generics may be shorter biosimilars will be longer than that.
The margins and lets stay with EBITDA margins would be north of 30% and may start out with between 25% to 30 because of these products are highly competitive.
Brian.
But as we can.
Come out as a cost or a second biosimilars just like pushed our second complex generics will be much higher than 30%.
Thanks for the comments.
Thank you and once again. Please press Star then one if you would like to ask a question.
And the next question comes from Gary Nachman with BMO capital markets.
Thanks, Good morning <unk>.
Robinson to when you're having discussions with different parties about expanding your portfolio what segments or technologies that you're most focused on or where you're seeing the most opportunities at this point.
Curious how competitive is the BD environment for assets, especially Biosimilars do you feel like sellers, our partners are being reasonable and what sort of advantages that you have in getting some of these deals done.
Thank you.
The portfolio on Biosimilars.
Yes.
We have gone Khalaji assets. So we will go for a few more oncology assets, where you will also go on to autoimmune then on.
On the <unk> side.
Site as well because we are.
<unk>.
Our long term buyers.
Follow on biologics platform, obtaining 15 years, just like we did with complex generics so we'll be pretty much looking at more of.
Where we can navigate the patent where we can.
We closed our second to market, even the small ones those are low how we build the complex generics portfolio. Those same thinking same playbook, we are using to come up with a biosimilar platform we signed.
On our Biosimilars actually assets that are available because the company's invested and lost.
At 10 years.
Mostly they focused on R&D.
And then they got stuck because of the situation in the United States.
And all of those.
How it goes with the branded companies it takes time to really launch.
The biosimilars. Unlike Europe. So there is excess capacity and manufacturing sitting out there, especially in Europe, and South Korea, and China. So we are tapping on to those and we do have existing two great partnership and we would probably explain to one more.
And manage with <unk> partners.
We can then bring.
Bringing manufacturing to the United States as well for many reasons, including the Pandemics and climate changes or emergencies.
<unk> manufacturing in the United States as well.
<unk>.
On water floating we put up a vaccine manufacturing expanded and it is helping we got or people vaccinated faster than other countries and we are now in a position to explore effects. So I believe.
And making it here would be.
We were ranked ages.
And other deals we're looking at is on our Parkinson's.
And the category, where we have leading edge they'd already commercial assets, we have IPX towards free which is coming up the topline results second half of this year.
And we like to consolidate it.
Holiday the space.
So that that's those are the main focus right now from expanding the portfolio.
Okay, and actually if I could just squeeze in one other just back to the gross margin. How many products are you shifting from external to internal manufacturing and how will that be safe to help the gross margin efficiencies over time.
Just talk about where you're getting most of the efficiencies in manufacturing.
Yes, sorry.
So pretty much on where work is done since we came back we have brought in most of the products in house.
On the partnered products such as Apple pay income comes from Pfizer and Philips or does take partnered very reliable great partners.
And we continue to expand that relationship.
Lower cutoffs in long Island partner Jerome Stevens is excellent over the years in loans the best quality.
Low tide oxen.
Yes.
In the market. So those are besides those we pretty much have brought a breathing late 14 or so products in house from various <unk>.
<unk>, which allowed us to now produce more and more on margins, so very very highly efficient already.
Yes.
That's spot on the other areas right. So we spent.
As seen on more than $500 million.
Kind of parts, you're seeing raw material. So that came that gives us a nice a nice opportunity for our strategic sourcing organization.
The same way our customers are pushing for price.
Is that kind of goes to other supply chain right. So I think thats, an area of opportunity as well as efficiencies within our own.
Mobile manufacturing footprint right.
And she's on the plant so it should change too and his team are very focused in that and we see this continue to produce.
Income for us.
From the foreseeable future share 91.
It's not done yet yeah, Real example, a year ago or back.
<unk> was $30 1 million last week is $1 million. So we have gained tremendous efficiencies fall across New Jersey operations in New York.
India and now island is coming up soon so.
Fantastic. Thank you.
Okay very helpful. Thank you.
Thank you.
That concludes our question and answer session as well as the call itself. Thank you. So much for attending today's presentation. You may now disconnect your lines.
Thank you.